Heterocyclic compounds exhibit significant biological activity and play a crucial role in the treatment of various diseases, including diabetes, Alzheimer’s, and cancer. Their diverse structural frameworks allow them to interact with a range of biological targets, making them valuable in drug development. Recent research has demonstrated their potential in developing more effective and targeted therapies for these conditions.

The aim of this study is to synthesize and biologically evaluate a new hybrid heterocyclic derivative for its antioxidant properties. We will investigate its effectiveness in neutralizing free radicals and protecting against oxidative stress. Furthermore, an in-silico study will be conducted to assess the compound's pharmacokinetic (ADMET) properties, evaluating its potential for medicinal applications and therapeutic efficacy.

A new derivative based on quinoléine has been successfully synthesized through a simple condensation reaction without the need for a catalyst, resulting in an excellent yield of 98-90%. These molecules underwent antioxidant testing to demonstrate their antioxidant activity, as well as theoretical simulation studies to verify their anticancer effects.

This study provides evidence that these molecules are significant bioactive compounds with substantial medicinal effects. Their pronounced biological activities highlight their potential as therapeutic agents in the treatment of various diseases. The findings suggest that these compounds could play a crucial role in drug development and offer new avenues for medical research and clinical applications.